Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients

Sacubitril/valsartan (Sac/Val) reduces mortality in patients with heart failure with reduced ejection fraction (HFrEF) compared to enalapril. However, its effects on functional capacity remain uncertain; consequently, we sought to compare Sac/Val vs. standard medical therapy, in terms of effects on...

Descripció completa

Dades bibliogràfiques

Autors principals:	Alfonso Campanile, Valeria Visco, Stefania De Carlo, Germano Junior Ferruzzi, Costantino Mancusi, Carmine Izzo, Felice Mongiello, Paola Di Pietro, Nicola Virtuoso, Amelia Ravera, Domenico Bonadies, Carmine Vecchione, Michele Ciccarelli
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2023-05-01
Col·lecció:	Life
Matèries:	sacubitril/valsartan heart failure HFrEF CPET exercise capacity peak VO<sub>2</sub>
Accés en línia:	https://www.mdpi.com/2075-1729/13/5/1174
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!